Hemostemix Ev To Operating Cash Flow vs Capex To Depreciation Analysis
HEM Stock | CAD 0.08 0.01 5.88% |
Hemostemix financial indicator trend analysis is much more than just examining Hemostemix latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Hemostemix is a good investment. Please check the relationship between Hemostemix Ev To Operating Cash Flow and its Capex To Depreciation accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hemostemix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
Ev To Operating Cash Flow vs Capex To Depreciation
Ev To Operating Cash Flow vs Capex To Depreciation Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Hemostemix Ev To Operating Cash Flow account and Capex To Depreciation. At this time, the significance of the direction appears to have significant contrarian relationship.
The correlation between Hemostemix's Ev To Operating Cash Flow and Capex To Depreciation is -0.21. Overlapping area represents the amount of variation of Ev To Operating Cash Flow that can explain the historical movement of Capex To Depreciation in the same time period over historical financial statements of Hemostemix, assuming nothing else is changed. The correlation between historical values of Hemostemix's Ev To Operating Cash Flow and Capex To Depreciation is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Ev To Operating Cash Flow of Hemostemix are associated (or correlated) with its Capex To Depreciation. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capex To Depreciation has no effect on the direction of Ev To Operating Cash Flow i.e., Hemostemix's Ev To Operating Cash Flow and Capex To Depreciation go up and down completely randomly.
Correlation Coefficient | -0.21 |
Relationship Direction | Negative |
Relationship Strength | Insignificant |
Ev To Operating Cash Flow
A valuation metric comparing the company's enterprise value to its operating cash flow, indicating how many dollars of EV are generated for each dollar of operating cash flows.Capex To Depreciation
The ratio of a company's capital expenditures to its depreciation expenses, indicating how much the company is investing in physical assets relative to the aging of existing assets.Most indicators from Hemostemix's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Hemostemix current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hemostemix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. Issuance Of Capital Stock is likely to climb to about 2.3 M in 2024, whereas Selling General Administrative is likely to drop slightly above 1.3 M in 2024.
Hemostemix fundamental ratios Correlations
Click cells to compare fundamentals
Hemostemix Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Hemostemix fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 104.3K | 2.3M | 563.0K | 465.3K | 313.8K | 298.1K | |
Other Current Liab | 2.1M | 3.2M | 1.0M | 2.6M | 3.0M | 3.2M | |
Total Current Liabilities | 4.1M | 3.4M | 4.4M | 2.6M | 2.9M | 2.4M | |
Total Stockholder Equity | (4.0M) | (1.1M) | (5.3M) | (6.8M) | (7.4M) | (7.0M) | |
Net Tangible Assets | 487.8K | (4.0M) | (1.1M) | (6.8M) | (6.1M) | (5.8M) | |
Net Debt | 2.0M | (83.0K) | 1.3M | 4.0M | 4.2M | 4.4M | |
Retained Earnings | (41.5M) | (49.2M) | (55.5M) | (60.8M) | (63.3M) | (60.1M) | |
Accounts Payable | 2.1M | 3.2M | 4.4M | 2.4K | 2.9M | 1.6M | |
Cash | 24.1K | 258.0K | 219.4K | 135.7K | 155.4K | 147.6K | |
Non Current Assets Total | 4.5K | 2.0K | 902.0 | 407.0 | 184.0 | 174.8 | |
Cash And Short Term Investments | 24.1K | 258.0K | 219.4K | 135.7K | 155.4K | 147.6K | |
Net Receivables | 75.8K | 2.1M | 342.7K | 138.9K | 25.1K | 23.8K | |
Common Stock Shares Outstanding | 15.0M | 32.2M | 57.4M | 70.0M | 82.5M | 86.6M | |
Liabilities And Stockholders Equity | 104.3K | 2.3M | 563.0K | 465.3K | 313.8K | 298.1K | |
Inventory | (88.2K) | (13.3K) | (45.5K) | (342.7) | (394.1) | (413.81) | |
Other Current Assets | 13.3K | 45.5K | 342.7 | 190.3K | 133.1K | 101.6K | |
Other Stockholder Equity | 6.0M | 8.7M | 10.1M | 10.2M | 11.9M | 12.5M | |
Total Liab | 4.1M | 3.4M | 5.8M | 7.2M | 7.7M | 8.1M | |
Total Current Assets | 99.8K | 2.3M | 562.1K | 464.9K | 313.6K | 297.9K | |
Accumulated Other Comprehensive Income | 439.7K | 1.5M | 1.5M | 2.7M | 1.5M | 1.5M | |
Net Invested Capital | (2.0M) | (923.7K) | (3.8M) | (2.6M) | (3.0M) | (2.9M) | |
Net Working Capital | (4.0M) | (1.1M) | (3.8M) | (2.2M) | (2.6M) | (2.4M) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Hemostemix Stock Analysis
When running Hemostemix's price analysis, check to measure Hemostemix's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hemostemix is operating at the current time. Most of Hemostemix's value examination focuses on studying past and present price action to predict the probability of Hemostemix's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hemostemix's price. Additionally, you may evaluate how the addition of Hemostemix to your portfolios can decrease your overall portfolio volatility.